Name: BIO
Brand: Selleck Chemicals
SKU: S7198
Rating: 5 (24 reviews)

CAS No. 667463-62-9

Selleck's BIO has been cited by 24 publications

Purity & Quality Control

Choose Selective GSK-3 Inhibitors

Related Compound Libraries

Other GSK-3 Products

Download Inhibitor Catalog

GSK-3 Signaling Pathway Map

Biological Activity

Description

BIO (GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, MLS 2052) is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3α/β in a cell-free assay, shows >16-fold selectivity over CDK5, also a pan-JAK inhibitor with IC50 of 30 nM for Tyk2. BIO induces apoptosis in human melanoma cells.

Features

The first pharmacological agent shown to maintain self-renewal in human and mouse embryonic stem cells.

Targets

GSK-3 ^[1] (Cell-free assay)	TYK2 ^[4] (Cell-free assay)	CDK5/p35 ^[1] (Cell-free assay)	CDK2/CyclinA ^[1] (Cell-free assay)	CDK1/CyclinB ^[1] (Cell-free assay)	Click to View More Targets
5 nM	30 nM	0.08 μM	0.30 μM	0.32 μM	Click to View More Targets

In vitro

BIO (6-bromoindirubin-3'-oxime) is a specific inhibitor of glycogen synthase kinase-3 (GSK-3), with IC50 of 5 nM for GSK-3α/β, shows >16-fold selectivity over CDK5. BIO interacts within the ATP binding pocket of these kinases, reduces β-catenin phosphorylation on a GSK-3-specific site in cellular models, closely mimicks Wnt signaling in Xenopus embryos. ^[1] In human and mouse embryonic stem cells, BIO maintains the undifferentiated phenotype and sustains expression of the pluripotent state-specific transcription factors Oct-3/4, Rex-1 and Nanog. BIO-mediated Wnt activation is functionally reversible, as withdrawal of the compound leads to normal multidifferentiation programs in both human and mouse embryonic stem cells. ^[2] BIO promotes proliferation in mammalian cardiomyocytes. ^[3]6BIO is also a pan-JAK inhibitor, with IC50 values of 0.03, 1.5, 8.0, 0.5 μM for TYK2, JAK1, JAK2 and JAK3. BIO selectively inhibits phosphorylation of STAT3 and induces apoptosis of human melanoma cells. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

HEI-OC1	NF;UUFFHfW6ldHnvckBie3OjeR?=			NWXONGpxWHKxdHXjeIlwdiCjZ3HpcpN1KGOrc4DsZZRqdi2rbnT1Z4VlKGOnbHyg[IVifGhiaX6gcoVwdmG2YXygcY92e2ViSFXJMW9EOSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4F{eGG\|ZT2zM\|ch[WO2aY\peJktKEWFNUCgQUAxNjF7MjFOwG0v	NUDKUHBIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwPVE6OTVpPkOwNFkyQTF3PD;hQi=>
SH-SY5Y	NV3TdWZ{TnWwY4Tpc44h[XO\|YYm=			MX3Jcohq[mm2aX;uJI9nKEeVS{OtcYVlcWG2ZXSgZoV1[S2lYYPlbY4heGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJHNJNVO\NWmgZ4VtdHNiaX6gdJJme2WwY3Wgc4YhVUdzM{KgZpkhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|LDDJR\|UxKD1iMD6yPUDPxE1w	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDhzNkGxNEc,OTh6MU[xNVA9N2F-
K562	NETuWGhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M{[weVczKGi{cx?=	MXHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEt3NkKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDFwMzFOwG0v	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd6M{G0PUc,OTl5OEOxOFk9N2F-
IMR90	NGPYfHNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MmHGO\|IhcHK\|	M4LVdmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSV3SPVAh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEGuPUDPxE1w	NYmzXWs4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3PFMyPDlpPkG5O\|g{OTR7PD;hQi=>
HCT116	M{f0NGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NWTJdll3PzJiaILz	M2LwbGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC1MlIh\|ryPLh?=	NUHWRnc3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3PFMyPDlpPkG5O\|g{OTR7PD;hQi=>
HepG2	MWnDfZRwfG:6aXPpeJkh[XO\|YYm=		MXeyOEBpenN?	MYfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyClZXzsJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEK0JIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IEWuN{DPxE1w	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDd2M{S5Nkc,Ojh5NEO0PVI9N2F-
HL60	MV;BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M3HvVlUh\GG7cx?=	MVXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNiYX\0[ZIhPSCmYYnzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDVwNDFOwG0v	NXfhV4NuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3PFMyPDlpPkG5O\|g{OTR7PD;hQi=>
HuH7	NFvsZYtCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MX23NkBpenN?	M1y4[GFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSIXIO{Bk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iNj6yJO69VS5?	NX;QWmlORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3PFMyPDlpPkG5O\|g{OTR7PD;hQi=>
SH-SY5Y	NXv6XXBxS3m2b4TvfIlkcXS7IHHzd4F6		MX20PEBpenN?	NELnT3hEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUC2VWUXZJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGOgdoVlfWO2aX;uJIF{e2G7LDDJR\|UxKD1iOTFOwG0v	NETzRms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEixOlEyOCd-MUi4NVYyOTB:L3G+
SH-SY5Y	NET5ZXJHfW6ldHnvckBie3OjeR?=		Mn7iOFghcHK\|	M4L6dHN2en[rdnHsJI9nKGi3bXHuJHNJNVO\NWmgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WUzDy[YR2[3Srb36gZZN{[XluIFnDOVAhRSB7LkWg{txONg>?	MmrFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ6NUSwOlkoRjF4OEW0NFY6RC:jPh?=
SH-SY5Y	MlPrSpVv[3Srb36gZZN{[Xl?			MV7E[YF1cCCxZjDoeY1idiCVSD3TXVV[KGOnbHzzJIlvKGGkc3XuZ4Uhd2ZiMkCgeW0hWS2YRD3PVIgh[nliTWTTJJJm\HWldHnvckBie3OjeTygTWM2OCB;IEGwJO69VS5?	NUfhd\|NDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[4OVQxPjlpPkG2PFU1ODZ7PD;hQi=>
SH-SY5Y	MYHGeY5kfGmxbjDhd5NigQ>?			NITWOIhF\WG2aDDv[kBpfW2jbjDTTE1UYTW\IHPlcIx{KGmwIIDy[ZNmdmOnIH;mJFIxKHWPIGGtWmQuV1CqIHL5JG1VWyC{ZXT1Z5Rqd25iYYPzZZktKEmFNUCgQUAyOyEQvF2u	MoXzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ6NUSwOlkoRjF4OEW0NFY6RC:jPh?=
SH-SY5Y	MWTGeY5kfGmxbjDhd5NigQ>?		NVfTfHBKOjRiaILz	NIrUeHRUfXK4aY\hcEBw\iCqdX3hckBUUC2VWUXZJINmdGy\|IHHmeIVzKDJ2IHjyd{BjgSCPVGOgdoVlfWO2aX;uJIF{e2G7LDDJR\|UxKD1iMUig{txONg>?	M2\tSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OEW0NFY6Lz5zNki1OFA3QTxxYU6=
IMR32	NIrHXYNEgXSxdH;4bYNqfHliYYPzZZk>		MXi0PEBpenN?	M4\XWWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGlOWjN{IHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZk>	MmL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MEK5OFcoRjJzOECyPVQ4RC:jPh?=
SK-N-SH	MmfQR5l1d3SxeHnjbZR6KGG\|c3H5		MUi0PEBpenN?	NYO0dW5ZS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0tvTj3TTEBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7	NYjue2VMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NFI6PDdpPkKxPFAzQTR5PD;hQi=>
NB39	MnXWR5l1d3SxeHnjbZR6KGG\|c3H5		NEK3[VY1QCCqcoO=	Mn:wR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmI{QSClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5	NHfCWnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUiwNlk1Pyd-MkG4NFI6PDd:L3G+
A673	MmH4dWhVWyCjc4PhfS=>			MkKzdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN?	NFnXO5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
DAOY	MnfhdWhVWyCjc4PhfS=>			MmT3dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN?	M1rBblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2	NFfhN2RyUFSVIHHzd4F6			NXvsR5g1eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	NV3ETnhIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37	MV3xTHRUKGG\|c3H5			MUTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
RD	M{fx[JFJXFNiYYPzZZk>			MnrwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{	NFq4c3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-SH	M3jqepFJXFNiYYPzZZk>			NYTQNnAyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM>	MoXEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-12	NWrQbmlZeUiWUzDhd5NigQ>?			M1qwUZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?=	NEfPOWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
MG 63 (6-TG R)	NELpeoJyUFSVIHHzd4F6			M2f4cpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?=	NUXae3QyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643	MWDxTHRUKGG\|c3H5			MULxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy\|	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	NWGyR\|I6eUiWUzDhd5NigQ>?			MXrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy\|	NHjtdZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	NV;Rd41IeUiWUzDhd5NigQ>?			NGXhOG1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh30	MUnxTHRUKGG\|c3H5			MkfkdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqM{CgZ4VtdHN?	NY\tT3lzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2	Ml\HdWhVWyCjc4PhfS=>			MknVdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	M1\Fb5FJXFNiYYPzZZk>			MVfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	NFPsVnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB-EBc1	MmnFdWhVWyCjc4PhfS=>			MWPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?=	Mn7BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	NH;PZVFyUFSVIHHzd4F6			MlOydWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy\|	MkXkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh18	MXXxTHRUKGG\|c3H5			NXzCVFdteUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO=	NIDFOmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
A549	MlLKSpVv[3Srb36gZZN{[Xl?	Ml:5NVAhfU1?	MlPXNVUhdWmwcx?=	NXm1VHN{UW6qaXLpeIlwdiCxZjDoeY1idiCvUFfFV\|Eh\nKxbTDoeY1idiCDNUS5JINmdGy\|IHHzd4V{e2WmIHHzJHBITTJiYYSgNVAhfU1iYX\0[ZIhOTVibXnud{BjgSCKUFzD	Mn25QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OUeyOFQoRjJ2Nkm3NlQ1RC:jPh?=
HEK293	NUTVRo1STnWwY4Tpc44h[XO\|YYm=	M1vNR\|AvPSC2bzCxJJVO		MYDJcohq[mm2aX;uJI9nKGi3bXHuJGdUUzNiYXP0bZZqfHliaX6gTGVMOjl\|IHPlcIx{KGOxboThbY5qdmdidHjlJHdvfC:kZYThMYNifGWwaX6gZYN1cX[jdHXkJJJmeG:{dHXyJJBUfXCncmTPVGZNSVOKIDjTWGYzQTNiY3XscJMqKGG2IECuOUB1dyBzIIXNJIJ6KFewdDDy[ZBwenSncjDn[Y5mKGG\|c3H5	NIDJ[Wo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[5O\|I1PCd-MkS2PVczPDR:L3G+
sf9	NGjEWVFHfW6ldHnvckBie3OjeR?=	NX;y[ndOOSC3TR?=		MkHsTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCQLYTldo1qdmGuIFfTWE11[WepZXSgR2RMPCBqU{SgeI8hTTNyMzDy[ZNq\HWnczmvR5lkdGmwIFSxJEhSPCC2bzDJNlk2KHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gd4Y6KGOnbHzzJIF1KDFidV2geZNqdmdiUlKtR3RHKGG\|IIP1ZpN1emG2ZTDifUBncWy2ZYKgZolv\GmwZzDhd5NigQ>?	Ml;KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3NUe0N\|AoRjJ6NUW3OFMxRC:jPh?=
sf9	MVzGeY5kfGmxbjDhd5NigQ>?	MV2xJJVO		MkS0TY5pcWKrdHnvckBw\iCqdX3hckBPNXSncn3pcoFtKEeVVD;IbZM3NXSjZ3fl[EBIW0t\|YnX0ZUApVTFidH:gWFQzOCC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKHOoOTDj[YxteyCjdDCxJJVOKHW\|aX7nJHJDTVJvSWLTeIll\SCjczDzeYJ{fHKjdHWgZpkh\mmudHXyJIJqdmSrbnegZZN{[Xl?	NXq1V\|NPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OVc1OzBpPkK4OVU4PDNyPD;hQi=>
sf9	MUTGeY5kfGmxbjDhd5NigQ>?	MlTHNUB2VQ>?		NFn0N4ZKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIF6teIVzdWmwYXygS3NVNXSjZ3fl[EBETEt{IDjNNUB1dyCOMkm4JJJme2mmdXXzLU9EgWOuaX6gRVIhME1zIITvJGw1OzJicnXzbYR2\XNrIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CC\|ZkmgZ4VtdHNiYYSgNUB2VSC3c3nu[{BJcXO2b37lJGgyKGG\|IIP1ZpN1emG2ZTDifUBncWy2ZYKgZolv\GmwZzDhd5NigQ>?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV3N{SzNEc,Ojh3NUe0N\|A9N2F-
sf9	MmP3SpVv[3Srb36gZZN{[Xl?	NEHuUmEyKHWP		MWPJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKE5vdHXycYlv[WxiR2PUMZRi\2enZDDDSGs2KCiPMTD0c{BROjl{IILld4llfWW\|KT;wN\|VPS0tiKF2xJJRwKFJ\|MEegdoV{cWS3ZYOpJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDz[lkh[2WubIOgZZQhOSC3TTD1d4lv\yCUQj3DWGYh[XNic4Xid5Rz[XSnIHL5JIZqdHSncjDibY5lcW6pIHHzd4F6	NWrVTGxpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OVc1OzBpPkK4OVU4PDNyPD;hQi=>
sf9	MoXGSpVv[3Srb36gZZN{[Xl?	MkjuNUB2VQ>?		M1vLVGlvcGmkaYTpc44hd2ZiaIXtZY4hVi22ZYLtbY5idCCJU2SvTIl{Pi22YXfn[YQhSXW{b4LhJGIhMEF{IITvJGE{PDRicnXzbYR2\XNrIHX4dJJme3OnZDDpckB{\jliY3XscJMh[XRiMTD1UUB2e2mwZzD0[ZRz[SiOUmLMV2xIMSCjczDzeYJ{fHKjdHWgZpkh\mmudHXyJIJqdmSrbnegZZN{[Xl?	NH\WW\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW1O\|Q{OCd-Mki1OVc1OzB:L3G+
sf9	M{i5OmZ2dmO2aX;uJIF{e2G7	NFv3dVEyKHWP		NV7HPJRRUW6qaXLpeIlwdiCxZjDoeY1idiCQLYTldo1qdmGuIFfTWE9JcXN4LYTh[4dm\CCIR1\SNUApTzRyMDD0c{BTQDJyIILld4llfWW\|KTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRic3[5JINmdGy\|IHH0JFEhfU1idYPpcochWG:ueTjHcJUtXHm{KUS6NUBieyC\|dXLzeJJifGViYomg[oltfGW{IHLpcoRqdmdiYYPzZZk>	NGfVcm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW1O\|Q{OCd-Mki1OVc1OzB:L3G+
sf9	NUP1UZpyTnWwY4Tpc44h[XO\|YYm=	MUOxJJVO		M{PYdWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iTj30[ZJucW6jbDDHV3QwUGm\|Nj30ZYdo\WRiQ1TLNUApVTFidH:gUVI6PyC{ZYPp[JVmeylxQ4njcIlvKEJzIDjNNUB1dyCYNEOzJJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5ic3[5JINmdGy\|IHH0JFEhfU1idYPpcochWkJvQ2TGJIF{KHO3YoP0doF1\SCkeTDmbYx1\XJiYnnu[Ilv\yCjc4PhfS=>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV3N{SzNEc,Ojh3NUe0N\|A9N2F-
sf9	MXjGeY5kfGmxbjDhd5NigQ>?	MYWxJJVO		M3XxS2lvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iTj30[ZJucW6jbDDHV3QufGGpZ3XkJGNFUzJiKF2xJJRwKEx{OUigdoV{cWS3ZYOpM2N6[2yrbjDFNUApVTFidH:gRVM6PSC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJJNnQSClZXzsd{BifCBzIIXNJJV{cW6pIGLCMWNVTiCjczDzeYJ{fHKjdHWgZpkh\mmudHXyJIJqdmSrbnegZZN{[Xl?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV3N{SzNEc,Ojh3NUe0N\|A9N2F-
sf9	NWrTXFNOTnWwY4Tpc44h[XO\|YYm=	MlL4NUB2VQ>?		MVnJcohq[mm2aX;uJI9nKGi3bXHuJG4ufGW{bXnuZYwhT1OWL1jpd\|YufGGpZ3XkJGF2em:{YTDBJEhOOSC2bzDTOFA{KHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhe2Z7IHPlcIx{KGG2IEGgeW0hfXOrbnegeIV1emFqTGLSUHNNTyliYYOgd5Vje3S{YYTlJIJ6KG[rbITldkBjcW6maX7nJIF{e2G7	NGfuXZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW1O\|Q{OCd-Mki1OVc1OzB:L3G+
sf9	NX3vbVA3TnWwY4Tpc44h[XO\|YYm=	MWSxJJVO		NH32NYpKdmirYnn0bY9vKG:oIHj1cYFvKE5vdHXycYlv[WxiR2PUMZRi\2enZDDBeZJwemFiQjCoUVEhfG9iU{K3JJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5ic3[5JINmdGy\|IHH0JFEhfU1idYPpcochS0SFMkXDMYRmemm4ZXSgdIVxfGmmZTDhd{B{fWK\|dILheIUh[nliZnnseIVzKGKrbnTpcoch[XO\|YYm=	NF74fGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW1O\|Q{OCd-Mki1OVc1OzB:L3G+
HT22	NHTLSmZHfW6ldHnvckBie3OjeR?=	MnrQNVAhfU1?	NU[zbW9EOjRiaILz	NH\vdm5KdmirYnn0bY9vKG:oIFfTT\|MudWWmaXH0[YQh[mW2YTDjZZNmcW5icHjvd5Bpd3K7bHH0bY9vKGmwIH3veZNmKEiWMkKgZ4VtdHNiYYSgNVAhfU1iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrczDpckBxemW\|ZX7j[UBw\iCPR{GzNi=>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl7OES0N{c,OjJ7OUi0OFM9N2F-

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	p-AKT / AKT / p21 / p27 ; p-β-catenin / β-catenin ; FoxO3a / FoxO1 / p-FoxO3a / p-FoxO1	27510556 27211495
Immunofluorescence	pAKT / p21 / p27 ; TNF-α ; E-cadherin / Nanog ; Oct3/4	27510556 24286133 25538040
Growth inhibition assay	Cell proliferation	27510556

In vivo

BIO suppresses melanoma tumor growth in a mouse xenograft model. ^[4]

Protocol (from reference)

Kinase Assay:^[1]	Kinase assay: Kinase activities are assayed in Buffer A or C at 30°C, at a final ATP concentration of 15 μM. Blank values are subtracted and activities calculated as pmoles of phosphate incorporated during a 10 min incubation. Controls are performed with appropriate dilutions of dimethylsulfoxide. In a few cases phosphorylation of the substrate is assessed by autoradiography after SDS-PAGE. GSK-3α/β is purified from porcine brain by affinity chromatography on immobilized axin. It is assayed, following a 1/100 dilution in 1 mg BSA/ml 10 mM DTT, with 5 μl 40 μM GS-1 peptide, a specific GSK-3 substrate, (YRRAAVPPSPSLSRHSSPHQSpEDEEE), in buffer A, in the presence of 15 μM [γ-³²P] ATP (3,000 Ci/mmol; 1 mCi/ml) in a final volume of 30 μl. After 30 min incubation at 30°C, 25 μl aliquots of supernatant are spotted onto 2.5 × 3 cm pieces of Whatman P81 phosphocellulose paper, and 20 seconds later, the filters are washed five times (for at least 5 min each time) in a solution of 10 ml phosphoric acid/liter of water. The wet filters are counted in the presence of 1 ml ACS scintillation fluid.
Cell Research:^[1]	Cell lines: COS1, Hepa or SH-SY5Y cells Concentrations: ~10 μM Incubation Time: 12 or 24 h Method: COS1, Hepa (wild-type, CEM/LM AhR deficient and ELB1 ARNT deficient), or SH-SY5Y cells are grown in 6 cm culture dishes in Dulbecco's Modified Medium (DMEM) containing 10% fetal bovine serum. For treatment, IO (5 μM), BIO (5 or 10 μM), MeBIO (5 or 50 μM), LiCl (20 or 40 mM), or mock solution (DMSO, 0.5% final concentration) is added to medium when cell density reaches ∼70% confluence. After 12 (SH-SY5Y) or 24 hours, the cells, while still in plate, are lysed with lysis buffer (1% SDS, 1 mM sodium orthovanadate, 10 mM Tris [pH 7.4]). The lysate is passed several times through a 26G needle, centrifuged at 10,000 × g for 5 min, and adjusted to equal protein concentration. About 8 μg of each sample is loaded for immunoblotting. Enhanced chemiluminescence is used for detection. The following primary antibodies are used: mouse anti-β-catenin CT (Upstate Biotechnolgies, Clone 7D8, recognizes total β-catenin), mouse anti-phospho-β-catenin (Upstate Biotechnologies, Clone 8E7, recognizes dephosphorylated β-catenin), mouse anti-GSK-3 β, mouse anti-GSK-3 phosphoTyr216, rabbit anti-AhR (Aryl hydrocarbon receptor), and rabbit anti-actin. (Only for Reference)
Animal Research:^[4]	Animal Models: mouse Dosages: 50 mg/kg Administration: Oral gavage (Only for Reference)

References

[4] Liu L, et al. Cancer Res. 2011 Jun 1;71(11):3972-3279.

+ Expand

Solubility (25°C)

In vitro	DMSO	71 mg/mL (199.34 mM)
	Water	Insoluble
	Ethanol	'6 mg/mL
In vivo	Add solvents to the product individually and in order (Data is from Selleck tests instead of citations): 5% DMSO+40% PEG 300+5% Tween 80+50%ddH2O For best results, use promptly after mixing. Click to purchase: PEG300 Tween 80	3 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight	356.17
Formula	C₁₆H₁₀BrN₃O₂
CAS No.	667463-62-9
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	C1=CC=C2C(=C1)C(=C(N2)C3=C(NC4=C3C=CC(=C4)Br)O)N=O

Download BIO SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04276857	Not yet recruiting	Device: Irreversible electroporation (NanoKnife® )	Locally Advanced Pancreatic Cancer\|Irreversible Electroporation	University of Saskatchewan	April 1 2022	Not Applicable
NCT04461301	Not yet recruiting	Procedure: Multimodal Prehabilitation	Frail Elderly Syndrome\|Major Surgery	University Hospital Inselspital Berne\|University of Bern	February 1 2022	Not Applicable
NCT05085730	Not yet recruiting	Device: InMode Morpheus8 System	Aging	University of Texas Southwestern Medical Center	February 1 2022	Not Applicable

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):